EFFECTOR Therapeutics Valuation
| EFTRWDelisted Stock | USD 0 0.00 0.00% |
EFFECTOR Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model computes the value of EFFECTOR Therapeutics from analyzing the firm fundamentals such as number of shares shorted of 18.44 K, and Net Income of (35.81 M) as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that EFFECTOR Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of EFFECTOR Therapeutics is based on 3 months time horizon. Increasing EFFECTOR Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the EFFECTOR pink sheet is determined by what a typical buyer is willing to pay for full or partial control of EFFECTOR Therapeutics. Since EFFECTOR Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of EFFECTOR Pink Sheet. However, EFFECTOR Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.001 | Real 9.5E-4 | Hype 0.00125 | Naive 0.00993 |
The intrinsic value of EFFECTOR Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence EFFECTOR Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of EFFECTOR Therapeutics helps investors to forecast how EFFECTOR pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of EFFECTOR Therapeutics more accurately as focusing exclusively on EFFECTOR Therapeutics' fundamentals will not take into account other important factors: EFFECTOR Therapeutics Total Value Analysis
EFFECTOR Therapeutics is currently projected to have takeover price of 0 with market capitalization of 0, debt of 19.45 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the EFFECTOR Therapeutics fundamentals before making investing decisions based on enterprise value of the companyEFFECTOR Therapeutics Asset Utilization
One of the ways to look at asset utilization of EFFECTOR is to check how much profit was generated for every dollar of assets it reports. EFFECTOR Therapeutics shows a negative utilization of assets of -0.83 percent, losing $0.008333 for each dollar of assets held by the firm. Inefficient asset utilization denotes the company is being less productive with each dollar of assets it shows. Put another way, asset utilization of EFFECTOR Therapeutics shows how inadequate it operates for each dollar spent on its assets.EFFECTOR Therapeutics Profitability Analysis
Net Loss for the year was (35.81 M) with profit before overhead, payroll, taxes, and interest of 0.About EFFECTOR Therapeutics Valuation
Our relative valuation model uses a comparative analysis of EFFECTOR Therapeutics. We calculate exposure to EFFECTOR Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of EFFECTOR Therapeutics's related companies.8 Steps to conduct EFFECTOR Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates EFFECTOR Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct EFFECTOR Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain EFFECTOR Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine EFFECTOR Therapeutics' revenue streams: Identify EFFECTOR Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research EFFECTOR Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish EFFECTOR Therapeutics' growth potential: Evaluate EFFECTOR Therapeutics' management, business model, and growth potential.
- Determine EFFECTOR Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate EFFECTOR Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
EFFECTOR Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as EFFECTOR Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 2.2 M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in EFFECTOR Pink Sheet
If you are still planning to invest in EFFECTOR Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EFFECTOR Therapeutics' history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |